{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-26-000047","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.885075+00:00","generated_at":"2026-05-15T04:24:15.505556+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance","bullets":["Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)","High-Value Components revenue $409.3M (+29.6%); HVP Delivery Devices $123.6M (+29.0%); West Vantage $150.6M (+11.6%)","Raised FY26 net sales guidance to $3.295-3.350B (prev $3.215-3.275B) and adj. EPS to $8.40-8.75 (prev $7.85-8.20)","Repurchased 1.2M shares for $297.6M at avg $243.57/share under February 2026 buyback program","Q2 2026 guidance introduced: net sales $830-850M, adj. EPS $2.05-2.12; SmartDose sale to AbbVie expected mid-year"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000047","json":"https://secwatch.observer/filing/0000105770-26-000047.json","markdown":"https://secwatch.observer/filing/0000105770-26-000047.md","text":"https://secwatch.observer/filing/0000105770-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/wst-20260423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:24:15.505556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d938775c856c1a397898f3a92c94192ec630c80a","claim":"WEST PHARMACEUTICAL SERVICES INC reported the first quarter of 2026 results: revenue $844.9 million, EPS $1.92. Guidance raised.","evidence_excerpt":"West Reports First-Quarter 2026 Results – Strong Start to the Year and Raising Full Year Revenue and EPS guidance Exton, PA, April 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period) • Net sales of $844.9 million increased 21.0%; organic growth was 15.3%. • Diluted earnings per share (\"EPS\") of $1.92 increased 56.1%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Revenue","value":"$844.9 million"},{"label":"EPS","value":"$1.92"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}